Nielka P Van Erp

List of Publications by Year
in descending order

112	3,021	186265	175258
papers	citations	28 h-index	52 g-index

112	112	112	3791
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The effect of chemotherapy on the exposureâ€“response relation of abiraterone in metastatic castrationâ€resistant prostate cancer. British Journal of Clinical Pharmacology, 2022, 88, 1170-1178.	2.4	5
2	Exposureâ€toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. International Journal of Cancer, 2022, 150, 308-316.	5.1	8
3	Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?. Aids, 2022, 36, 322-323.	2.2	1
4	Exposureâ€“response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer, 2022, 22, 228.	2.6	11
5	Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer Chemotherapy and Pharmacology, 2022, 89, 697-705.	2.3	0
6	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5051-5051.	1.6	2
7	Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer. Biomedicine and Pharmacotherapy, 2022, 153, 113393.	5.6	3
8	The relationship between sunitinib exposure and both efficacy and toxicity in realâ€world patients with renal cell carcinoma and gastrointestinal stromal tumour. British Journal of Clinical Pharmacology, 2021, 87, 326-335.	2.4	18
9	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. Clinical Pharmacokinetics, 2021, 60, 191-203.	3.5	7
10	Comments on â€œSystemic exposure of oxaliplatin and docetaxel in gastric patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapyâ€. European Journal of Surgical Oncology, 2021, 47, 1216-1217.	1.0	0
11	Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof. Clinical Cancer Research, 2021, 27, 1830-1832.	7.0	4
12	Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapyâ€“naÃ¯ve patient: a case report. Cancer Chemotherapy and Pharmacology, 2021, 88, 165-168.	2.3	2
13	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castrationâ€resistant prostate cancer undergoing firstâ€line abiraterone acetate and prednisone treatment. Molecular Oncology, 2021, 15, 2453-2465.	4.6	9
14	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. Cancer Treatment Reviews, 2021, 97, 102171.	7.7	8
15	Dose finding of oncolytic combination therapy: Essential to secure the patient's quality of life. European Journal of Cancer, 2021, , .	2.8	1
16	The impact of a 1â€hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. International Journal of Cancer, 2021, 148, 2799-2806.	5.1	8
17	Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer Chemotherapy and Pharmacology, 2021, , 1.	2.3	2
18	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6279.	3.7	5

#	Article	IF	Citations
19	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 219-230.	3.1	36
20	Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLCâ€“MS/MS. Biomedical Chromatography, 2020, 34, e4758.	1.7	35
21	Imatinib, sunitinib and pazopanib: From flatâ€fixed dosing towards a pharmacokinetically guided personalized dose. British Journal of Clinical Pharmacology, 2020, 86, 258-273.	2.4	56
22	Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma. Therapeutic Drug Monitoring, 2020, 42, 146-150.	2.0	4
23	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNAâ€“Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 714-729.	3.0	18
24	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer Chemotherapy and Pharmacology, 2020, 86, 141-150.	2.3	3
25	Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. Journal of Oncology Pharmacy Practice, 2020, 26, 1850-1856.	0.9	1
26	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. Cancer Chemotherapy and Pharmacology, 2020, 85, 753-760.	2.3	5
27	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
28	Reply to â€˜Hyperthermic intraperitoneal chemotherapy with oxaliplatinâ€”Still not standard of care for patients with colorectal peritoneal metastasesâ€™ by Julianov and Saroglu. British Journal of Clinical Pharmacology, 2019, 85, 1848-1849.	2.4	1
29	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Targeted Oncology, 2019, 14, 441-451.	3.6	11
30	The effect of gastrectomy on regorafenib exposure and progressionâ€free survival in patients with advanced gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2019, 85, 2399-2404.	2.4	5
31	Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharmaceutical Research, 2019, 36, 163.	3.5	5
32	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical Research, 2019, 36, 181.	3.5	4
33	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2019, 84, 1179-1185.	2.3	9
34	Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. Annals of Oncology, 2019, 30, v161.	1.2	3
35	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). Clinical Pharmacology and Therapeutics, 2019, 106, 1076-1082.	4.7	26
36	Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution â€“ Authors' reply. Lancet Oncology, The, 2019, 20, e290.	10.7	0

#	Article	IF	Citations
37	Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A costâ€effectiveness study. British Journal of Clinical Pharmacology, 2019, 85, 1994-2001.	2.4	24
38	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Research, 2019, 39, 1309-1316.	1.1	8
39	Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncology, The, 2019, 20, e200-e207.	10.7	68
40	Impact of Concomitant Administration of Gastric Acidâ€“Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clinical Cancer Research, 2019, 25, 1479-1485.	7.0	63
41	Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Groupâ€“Therapeutic Drug Monitoring Protocol for a Prospective Study. Therapeutic Drug Monitoring, 2019, 41, 561-567.	2.0	33
42	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. Clinical Pharmacokinetics, 2019, 58, 651-658.	3.5	20
43	Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharmaceutical Research, 2019, 36, 33.	3.5	6
44	Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1105, 76-84.	2.3	33
45	Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. Acta OncolÃ³gica, 2019, 58, 128-131.	1.8	0
46	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. European Urology, 2019, 75, 351-352.	1.9	7
47	Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. British Journal of Clinical Pharmacology, 2019, 85, 47-58.	2.4	19
48	Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1110-1111, 15-24.	2.3	28
49	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. Journal of Clinical Oncology, 2019, 37, 4564-4564.	1.6	2
50	The impact of gastric acid suppressive agents on pazopanib exposure.. Journal of Clinical Oncology, 2019, 37, e16076-e16076.	1.6	1
51	Does a food intervention makes abiraterone treatment affordable?. Journal of Clinical Oncology, 2019, 37, e16523-e16523.	1.6	0
52	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.. Journal of Clinical Oncology, 2019, 37, e22511-e22511.	1.6	0
53	Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors. , 2019, , .		0
54	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Targeted Oncology, 2018, 13, 363-370.	3.6	4

#	Article	IF	Citations
55	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castrationâ€“Resistant Prostate Cancer. Therapeutic Drug Monitoring, 2018, 40, 222-229.	2.0	11
56	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castrationâ€resistant metastatic prostate cancer. British Journal of Clinical Pharmacology, 2018, 84, 1064-1067.	2.4	7
57	Development and validation of an analytical method using UPLCâ€“MS/MS to quantify everolimus in dried blood spots in the oncology setting. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 106-113.	2.8	23
58	Drugâ€“drug interaction potential in men treated with enzalutamide: Mind the gap. British Journal of Clinical Pharmacology, 2018, 84, 122-129.	2.4	41
59	Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate. Journal of Clinical Oncology, 2018, 36, 3062-3064.	1.6	6
60	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. Targeted Oncology, 2018, 13, 641-648.	3.6	10
61	Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).. Journal of Clinical Oncology, 2018, 36, 11555-11555.	1.6	2
62	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. Journal of Clinical Oncology, 2018, 36, 1062-1062.	1.6	0
63	Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. Journal of Clinical Oncology, 2018, 36, e18574-e18574.	1.6	0
64	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2525.	3.6	55
65	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 197-205.	2.8	29
66	Poorly specified fasting conditions in clinical research could lead to treatment failure. Lancet Oncology, The, 2017, 18, 571-573.	10.7	3
67	Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2017, 39, 269-272.	2.0	17
68	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British Journal of Clinical Pharmacology, 2017, 83, 2195-2204.	2.4	61
69	Analytical challenges in quantifying abiraterone with LCâ€“MS/MS in human plasma. Biomedical Chromatography, 2017, 31, e3986.	1.7	20
70	Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. Acta OncolÃ³gica, 2017, 56, 1238-1240.	1.8	16
71	Fasting conditions in clinical oncology trials and drug labelling â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e507.	10.7	0
72	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. British Journal of Clinical Pharmacology, 2017, 83, 2312-2314.	2.4	7

#	Article	IF	Citations
73	Fatal heart failure in a young adult female sarcoma patient treated with pazopanib. Acta OncolÃ³gica, 2017, 56, 1233-1234.	1.8	8
74	Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics, 2017, 56, 293-303.	3.5	35
75	Use of incretin agents and risk of acute and chronic pancreatitis: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2017, 19, 401-411.	4.4	20
76	Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.. Journal of Clinical Oncology, 2017, 35, 9540-9540.	1.6	0
77	<scp>mTOR</scp> inhibitorâ€induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. International Journal of Cancer, 2016, 138, 2312-2321.	5.1	76
78	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clinical Pharmacokinetics, 2016, 55, 1447-1456.	3.5	17
79	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discovery Today, 2016, 21, 962-976.	6.4	46
80	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18 F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. European Journal of Cancer, 2016, 56, 54-58.	2.8	9
81	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clinical Pharmacokinetics, 2016, 55, 1369-1380.	3.5	74
82	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	4.4	10
83	Everolimus pharmacokinetics and its exposureâ€“toxicity relationship in patients with thyroid cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 63-71.	2.3	34
84	A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. Anti-Cancer Drugs, 2016, 27, 576-579.	1.4	1
85	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. Journal of Clinical Oncology, 2016, 34, 11040-11040.	1.6	3
86	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	1.6	1
87	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	1.6	0
88	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. Therapeutic Drug Monitoring, 2015, 37, 501-507.	2.0	13
89	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. Journal of Clinical Pharmacology, 2015, 55, 1344-1350.	2.0	26
90	Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. Therapeutic Drug Monitoring, 2015, 37, 331-338.	2.0	48

#	Article	IF	Citations
91	Integrated semiâ€physiological pharmacokinetic model for both sunitinib and its active metabolite <scp>SU</scp>12662. British Journal of Clinical Pharmacology, 2015, 79, 809-819.	2.4	25
92	Promising management of pazopanib-induced liver toxicity. Acta OncolÃ³gica, 2015, 54, 1064-1066.	1.8	8
93	Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery. European Journal of Clinical Pharmacology, 2015, 71, 1279-1281.	1.9	6
94	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. Drug Discovery Today, 2015, 20, 18-36.	6.4	72
95	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 87-96.	2.3	24
96	Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer, 2014, 14, 575.	2.6	13
97	Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxÂ®). Cancer Chemotherapy and Pharmacology, 2014, 74, 457-463.	2.3	15
98	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 937, 33-43.	2.3	71
99	Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncology, 2013, 9, 1883-1892.	2.4	68
100	Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure. Journal of Clinical Oncology, 2013, 31, e83-e86.	1.6	13
101	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3495-3503.	3.6	146
102	Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemotherapy and Pharmacology, 2011, 67, 695-703.	2.3	45
103	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. European Journal of Endocrinology, 2011, 164, 621-626.	3.7	99
104	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. Clinical Cancer Research, 2011, 17, 620-629.	7.0	150
105	Myelosuppression by sunitinib is flt-3 genotype dependent. British Journal of Cancer, 2010, 103, 757-758.	6.4	19
106	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. Journal of Clinical Oncology, 2009, 27, 4406-4412.	1.6	177
107	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2009, 35, 692-706.	7.7	437
108	Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. Clinical Cancer Research, 2008, 14, 8308-8313.	7.0	20

#	Article	IF	Citations
109	Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Clinical Cancer Research, 2007, 13, 7394-7400.	7.0	107
110	Is rectal administration an alternative route for imatinib?. Cancer Chemotherapy and Pharmacology, 2007, 60, 623-624.	2.3	6
111	Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan. Clinical Cancer Research, 2005, 11, 7800-7806.	7.0	115
112	Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry, 2002, 47, 66-71.	1.8	24